Physician profile
David W Sullivan
NPI 1851399638
$12,953.90
in general payments reported to CMS, 2019-2025
71 companies · $2,594 in 2025
The $2,594 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,262 · 2020: $481 · 2021: $181 · 2022: $2,372 · 2023: $2,359 · 2024: $2,705 · 2025: $2,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,479 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,478.84 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $961.19 | 2019-2025 | |
| Pfizer INC. | $893.32 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $892.15 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Merck Sharp & Dohme LLC | $844.78 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Gilead Sciences, INC. | $698.66 | 2021-2025 | Trodelvy |
| Celgene Corporation | $694.47 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Janssen Biotech, INC. | $619.28 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $545.53 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Amgen INC. | $524.60 | 2019-2023 | Lumakras, Nplate, Xgeva |
| Lilly USA, LLC | $521.96 | 2019-2025 | Jaypirca, Verzenio |
| Abbvie INC. | $419.81 | 2019-2025 | Venclexta |
| Daiichi Sankyo INC. | $389.14 | 2019-2025 | Enhertu, Injectafer |
| Glaxosmithkline, LLC. | $331.78 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $308.43 | 2019-2025 | Ninlaro |
| Astellas Pharma US INC | $298.67 | 2019-2025 | Vyloy, Xtandi, Xospata |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $290.81 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Seagen INC. | $287.54 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Genentech USA, INC. | $259.74 | 2019-2025 | Perjeta, Phesgo, Polivy |
| Eisai INC. | $245.19 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.02 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Bayer Healthcare Pharmaceuticals INC. | $189.61 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $182.32 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Exelixis INC. | $131.42 | 2022-2025 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $120.79 | 2019-2024 | Ultomiris |
| Tempus Ai, INC | $109.71 | 2024-2025 | Xt Cdx |
| Emd Serono, INC. | $105.76 | 2023-2025 | Bavencio, Tepmetko |
| Janssen Pharmaceuticals, INC | $105.32 | 2019-2023 | Xarelto |
| Mirati Therapeutics, INC. | $89.01 | 2023-2024 | Krazati |
| Tesaro, INC. | $82.51 | 2019 | |
| Servier Pharmaceuticals LLC | $82.15 | 2023-2025 | |
| Puma Biotechnology, INC. | $82.12 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $79.75 | 2024-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $78.62 | 2022-2023 | Imbruvica |
| Sobi, INC | $72.30 | 2022 | |
| Aveo Pharmaceuticals, INC. | $71.15 | 2022-2025 | |
| Amag Pharmaceuticals, INC. | $68.94 | 2019-2020 | |
| Beigene USA, INC. | $68.09 | 2022-2025 | Brukinsa |
| Kite Pharma, INC. | $64.56 | 2022-2025 | Yescarta |
| Coherus Oncology, INC. | $64.47 | 2022-2025 | Loqtorzi |
| Genmab U.S., INC. | $63.12 | 2024-2025 | Epkinly |
| Sumitomo Pharma America, INC. | $57.63 | 2023 | Orgovyx |
| Genzyme Corporation | $51.53 | 2019-2022 | |
| Blueprint Medicines Corporation | $51.29 | 2020-2024 | Ayvakit |
| Stemline Therapeutics INC. | $43.52 | 2023-2024 | Orserdu |
| Geron Corporation | $42.57 | 2025 | Rytelo |
| Kyowa Kirin, INC. | $42.27 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $36.91 | 2023-2025 | Zepzelca |
| Beone Medicines USA, INC. | $36.55 | 2025 | Tevimbra |
| Taiho Oncology, INC. | $36.25 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $34.27 | 2022-2024 | Xpovio |
| Morphosys, US INC. | $30.00 | 2022-2023 | Monjuvi |
| Teva Pharmaceuticals USA, INC. | $27.59 | 2019 | |
| Secura Bio, INC. | $23.45 | 2019-2022 | |
| Sanofi US Services INC. | $22.32 | 2025 | |
| Legend Biotech USA INC. | $21.63 | 2025 | Carvykti |
| Octapharma USA, INC. | $21.47 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $21.43 | 2021 | |
| Biocompatibles, INC. | $19.71 | 2019 | |
| Adc Therapeutics America, INC. | $17.91 | 2023 | |
| Acrotech Biopharma INC. | $17.88 | 2025 | Beleodaq |
| Foundation Medicine, INC. | $17.84 | 2022 | |
| Tersera Therapeutics LLC | $17.13 | 2024 | Zoladex |
| Apellis Pharmaceuticals, INC. | $16.40 | 2023 | Empaveli |
| Pharmacosmos Therapeutics INC. | $16.24 | 2024 | Cosela |
| Boston Scientific Corporation | $14.89 | 2019 | |
| G1 Therapeutics, INC. | $14.75 | 2023 | Cosela |
| Dendreon Pharmaceuticals LLC | $14.09 | 2019 | |
| Novo Nordisk INC | $13.66 | 2024 | Wegovy, Saxenda |
| Dova Pharmaceuticals | $13.42 | 2019 | |
| Verastem, INC. | $12.43 | 2019 | |
| Advanced Accelerator Applications | $12.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.